Prevention of cutaneous damages induced by radiotherapy in breast cancer: An institutional experience

Vincenzo Ravo, Maria Grazia Calvanese, Rossella Di Franco, Vincenzina Crisci, Paola Murino, Roberto Manzo, Anna Morra, Fabrizio Cammarota, Paolo Muto

Research output: Contribution to journalArticle

Abstract

Background and aims. A minimal part of patients treated with radiotherapy on the entire breast may present an acute, subacute or chronic cutaneous damage of the healthy tissues involved in the radiation fields. The aim of this retrospective study was to evaluate the most efficient topical hydrating treatment in the prevention of cutaneous radio-induced acute effects in breast cancer. Material and methods. From February 2009 to March 2010, 100 patients affected by breast cancer have been recruited, all of the female sex and with an average age of 47 years. The following topical treatments were compared: Pure vitamin E (Vea lipogel®), Omega-3,6,9 (Quinovit®), Betaglucan, sodium hyaluronate (Neoviderm®), Vitis vinifera A.s-I-M.t-O.dij, (Ixoderm®), natural triglycerides-fitosterols (Xderit®). All enrolled patients were subjected to breast conservative treatment (quadrantectomy with or without homolateral axillary dissection) and without prosthesis positioning, in combination or not with hormonal treatment. Evaluation of the cutaneous acute toxicity was defined according to the RTOG scale either during radiotherapy and during follow-up (3 months after radiation treatment). Results. All patients completed the radiotherapy; 62% of patients presented G0-G1 cutaneous toxicity, 28% have developed G2 cutaneous toxicity, 10% have developed G3 toxicity; no patient presented G4 toxicity. Analysis of the data revealed a correlation between the topical treatment used and the incidence of cutaneous toxicity. Conclusions. Of the patients who used the cutaneous hydrating creams - betaglucan, sodium hyaluronate (Neoviderm®) and Vitis vinifera A.s-I-M.t-O.dij (Ixoderm®) - during the radiation treatment, 80% developed G0-G1 toxicity and 20% G2 toxicity. The patients who used the other hydrating creams tested in the study manifested not only G1-G2 toxicity but also some G3 toxicity. Chemotherapeutic treatment with taxanes and/or anthracyclines did not result in an increased breast cutaneous toxicity induced by radiotherapy. The hormone therapy given to patients undergoing radiotherapy did not result in increased breast cutaneous toxicity. Further analysis on a larger number of patients is necessary for definitive results.

Original languageEnglish
Pages (from-to)732-736
Number of pages5
JournalTumori
Volume97
Issue number6
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Radiotherapy
Breast Neoplasms
Skin
Breast
Vitis
Hyaluronic Acid
Therapeutics
Radiation
Skin Cream
Taxoids
Anthracyclines
Radio
Vitamin E
Prostheses and Implants
Dissection
Triglycerides
Retrospective Studies
Hormones
Incidence

Keywords

  • Breast cancer
  • Cutaneous damage
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prevention of cutaneous damages induced by radiotherapy in breast cancer : An institutional experience. / Ravo, Vincenzo; Calvanese, Maria Grazia; Di Franco, Rossella; Crisci, Vincenzina; Murino, Paola; Manzo, Roberto; Morra, Anna; Cammarota, Fabrizio; Muto, Paolo.

In: Tumori, Vol. 97, No. 6, 11.2011, p. 732-736.

Research output: Contribution to journalArticle

Ravo, V, Calvanese, MG, Di Franco, R, Crisci, V, Murino, P, Manzo, R, Morra, A, Cammarota, F & Muto, P 2011, 'Prevention of cutaneous damages induced by radiotherapy in breast cancer: An institutional experience', Tumori, vol. 97, no. 6, pp. 732-736. https://doi.org/10.1700/1018.11089
Ravo, Vincenzo ; Calvanese, Maria Grazia ; Di Franco, Rossella ; Crisci, Vincenzina ; Murino, Paola ; Manzo, Roberto ; Morra, Anna ; Cammarota, Fabrizio ; Muto, Paolo. / Prevention of cutaneous damages induced by radiotherapy in breast cancer : An institutional experience. In: Tumori. 2011 ; Vol. 97, No. 6. pp. 732-736.
@article{288e53b897914c4eb67eba5017bc1591,
title = "Prevention of cutaneous damages induced by radiotherapy in breast cancer: An institutional experience",
abstract = "Background and aims. A minimal part of patients treated with radiotherapy on the entire breast may present an acute, subacute or chronic cutaneous damage of the healthy tissues involved in the radiation fields. The aim of this retrospective study was to evaluate the most efficient topical hydrating treatment in the prevention of cutaneous radio-induced acute effects in breast cancer. Material and methods. From February 2009 to March 2010, 100 patients affected by breast cancer have been recruited, all of the female sex and with an average age of 47 years. The following topical treatments were compared: Pure vitamin E (Vea lipogel{\circledR}), Omega-3,6,9 (Quinovit{\circledR}), Betaglucan, sodium hyaluronate (Neoviderm{\circledR}), Vitis vinifera A.s-I-M.t-O.dij, (Ixoderm{\circledR}), natural triglycerides-fitosterols (Xderit{\circledR}). All enrolled patients were subjected to breast conservative treatment (quadrantectomy with or without homolateral axillary dissection) and without prosthesis positioning, in combination or not with hormonal treatment. Evaluation of the cutaneous acute toxicity was defined according to the RTOG scale either during radiotherapy and during follow-up (3 months after radiation treatment). Results. All patients completed the radiotherapy; 62{\%} of patients presented G0-G1 cutaneous toxicity, 28{\%} have developed G2 cutaneous toxicity, 10{\%} have developed G3 toxicity; no patient presented G4 toxicity. Analysis of the data revealed a correlation between the topical treatment used and the incidence of cutaneous toxicity. Conclusions. Of the patients who used the cutaneous hydrating creams - betaglucan, sodium hyaluronate (Neoviderm{\circledR}) and Vitis vinifera A.s-I-M.t-O.dij (Ixoderm{\circledR}) - during the radiation treatment, 80{\%} developed G0-G1 toxicity and 20{\%} G2 toxicity. The patients who used the other hydrating creams tested in the study manifested not only G1-G2 toxicity but also some G3 toxicity. Chemotherapeutic treatment with taxanes and/or anthracyclines did not result in an increased breast cutaneous toxicity induced by radiotherapy. The hormone therapy given to patients undergoing radiotherapy did not result in increased breast cutaneous toxicity. Further analysis on a larger number of patients is necessary for definitive results.",
keywords = "Breast cancer, Cutaneous damage, Radiotherapy",
author = "Vincenzo Ravo and Calvanese, {Maria Grazia} and {Di Franco}, Rossella and Vincenzina Crisci and Paola Murino and Roberto Manzo and Anna Morra and Fabrizio Cammarota and Paolo Muto",
year = "2011",
month = "11",
doi = "10.1700/1018.11089",
language = "English",
volume = "97",
pages = "732--736",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Prevention of cutaneous damages induced by radiotherapy in breast cancer

T2 - An institutional experience

AU - Ravo, Vincenzo

AU - Calvanese, Maria Grazia

AU - Di Franco, Rossella

AU - Crisci, Vincenzina

AU - Murino, Paola

AU - Manzo, Roberto

AU - Morra, Anna

AU - Cammarota, Fabrizio

AU - Muto, Paolo

PY - 2011/11

Y1 - 2011/11

N2 - Background and aims. A minimal part of patients treated with radiotherapy on the entire breast may present an acute, subacute or chronic cutaneous damage of the healthy tissues involved in the radiation fields. The aim of this retrospective study was to evaluate the most efficient topical hydrating treatment in the prevention of cutaneous radio-induced acute effects in breast cancer. Material and methods. From February 2009 to March 2010, 100 patients affected by breast cancer have been recruited, all of the female sex and with an average age of 47 years. The following topical treatments were compared: Pure vitamin E (Vea lipogel®), Omega-3,6,9 (Quinovit®), Betaglucan, sodium hyaluronate (Neoviderm®), Vitis vinifera A.s-I-M.t-O.dij, (Ixoderm®), natural triglycerides-fitosterols (Xderit®). All enrolled patients were subjected to breast conservative treatment (quadrantectomy with or without homolateral axillary dissection) and without prosthesis positioning, in combination or not with hormonal treatment. Evaluation of the cutaneous acute toxicity was defined according to the RTOG scale either during radiotherapy and during follow-up (3 months after radiation treatment). Results. All patients completed the radiotherapy; 62% of patients presented G0-G1 cutaneous toxicity, 28% have developed G2 cutaneous toxicity, 10% have developed G3 toxicity; no patient presented G4 toxicity. Analysis of the data revealed a correlation between the topical treatment used and the incidence of cutaneous toxicity. Conclusions. Of the patients who used the cutaneous hydrating creams - betaglucan, sodium hyaluronate (Neoviderm®) and Vitis vinifera A.s-I-M.t-O.dij (Ixoderm®) - during the radiation treatment, 80% developed G0-G1 toxicity and 20% G2 toxicity. The patients who used the other hydrating creams tested in the study manifested not only G1-G2 toxicity but also some G3 toxicity. Chemotherapeutic treatment with taxanes and/or anthracyclines did not result in an increased breast cutaneous toxicity induced by radiotherapy. The hormone therapy given to patients undergoing radiotherapy did not result in increased breast cutaneous toxicity. Further analysis on a larger number of patients is necessary for definitive results.

AB - Background and aims. A minimal part of patients treated with radiotherapy on the entire breast may present an acute, subacute or chronic cutaneous damage of the healthy tissues involved in the radiation fields. The aim of this retrospective study was to evaluate the most efficient topical hydrating treatment in the prevention of cutaneous radio-induced acute effects in breast cancer. Material and methods. From February 2009 to March 2010, 100 patients affected by breast cancer have been recruited, all of the female sex and with an average age of 47 years. The following topical treatments were compared: Pure vitamin E (Vea lipogel®), Omega-3,6,9 (Quinovit®), Betaglucan, sodium hyaluronate (Neoviderm®), Vitis vinifera A.s-I-M.t-O.dij, (Ixoderm®), natural triglycerides-fitosterols (Xderit®). All enrolled patients were subjected to breast conservative treatment (quadrantectomy with or without homolateral axillary dissection) and without prosthesis positioning, in combination or not with hormonal treatment. Evaluation of the cutaneous acute toxicity was defined according to the RTOG scale either during radiotherapy and during follow-up (3 months after radiation treatment). Results. All patients completed the radiotherapy; 62% of patients presented G0-G1 cutaneous toxicity, 28% have developed G2 cutaneous toxicity, 10% have developed G3 toxicity; no patient presented G4 toxicity. Analysis of the data revealed a correlation between the topical treatment used and the incidence of cutaneous toxicity. Conclusions. Of the patients who used the cutaneous hydrating creams - betaglucan, sodium hyaluronate (Neoviderm®) and Vitis vinifera A.s-I-M.t-O.dij (Ixoderm®) - during the radiation treatment, 80% developed G0-G1 toxicity and 20% G2 toxicity. The patients who used the other hydrating creams tested in the study manifested not only G1-G2 toxicity but also some G3 toxicity. Chemotherapeutic treatment with taxanes and/or anthracyclines did not result in an increased breast cutaneous toxicity induced by radiotherapy. The hormone therapy given to patients undergoing radiotherapy did not result in increased breast cutaneous toxicity. Further analysis on a larger number of patients is necessary for definitive results.

KW - Breast cancer

KW - Cutaneous damage

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84856912034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856912034&partnerID=8YFLogxK

U2 - 10.1700/1018.11089

DO - 10.1700/1018.11089

M3 - Article

C2 - 22322839

AN - SCOPUS:84856912034

VL - 97

SP - 732

EP - 736

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 6

ER -